The raising allows the client to enter the European, Australian, and US markets, a lead partner says
A US-based company is aiming to commercially launch in multiple markets after a successful debut on the ASX.
Johnson Winter & Slattery (JWS) was the Australian legal counsel to Imricor Medical systems on its IPO of CHESS Depositary Interests and listing on the ASX, as well as the legal counsel for the company on its pre-IPO financing.
Imricor raised $29.7m from the transactions, JWS said. The IPO raised $12.1m with support from Australian institutional and retail investors, as well as institutional investors abroad.
The JWS team was headed by partners James Rozsa and Clare Brown. They were supported by senior associates Scott Cummins and Melanie Hemers, as well as associates Jack Culbertson and Rebecca Proudman.
“The funds generated from this transaction will be used to enable the commercial launch of Imricor’s product portfolio allowing the company to enter the markets in Europe, Australia and the US. With this investment, Imricor will be one of the first companies to give patients with abnormal heart rates commercially viable MRI-compatible products,” Rozsa said.
Imricor designs, manufactures, and sells medical devices that can be used to carry out cardiac ablation procedures for the treatment of heart arrhythmias. Its main product, Vision-MRI Ablation Catheter, is designed to work under real-time MRI guidance.
James Rozsa
